For cultures treated with pomalidomide, cells were incubated with 1 mM pomalidomide (Sigma) as previously described,11 (link) starting from day 1 (D1) of phase II of culture. For γ-globin derepression experiments using CRISPR/Cas9, patient CD34+ cells were immunoselected and cultured for 48 hours (h) and then electroporated with ribonucleoprotein (RNP) complexes containing Cas9-GFP protein (4.5 mM) and the -197 guide RNA (gRNA) targeting both HBG1 and HBG2 γ-globin promoters (5’ ATTGAGATAGTGTGGGGAAGGGG 3’; protospacer adjacent motif in bold) or a gRNA targeting the Adeno-associated virus integration site 1 (AAVS1; 5’ GGGGCCACTAGGGACAGGATTGG 3’; protospacer adjacent motif in bold).12 (link) Cleavage efficiency was evaluated in cells harvested 6 days after electroporation by Sanger sequencing followed by tracking of indels by decomposition (TIDE) analysis.13 (link)
Isolation and CRISPR/Cas9 Editing of CD34+ Cells
For cultures treated with pomalidomide, cells were incubated with 1 mM pomalidomide (Sigma) as previously described,11 (link) starting from day 1 (D1) of phase II of culture. For γ-globin derepression experiments using CRISPR/Cas9, patient CD34+ cells were immunoselected and cultured for 48 hours (h) and then electroporated with ribonucleoprotein (RNP) complexes containing Cas9-GFP protein (4.5 mM) and the -197 guide RNA (gRNA) targeting both HBG1 and HBG2 γ-globin promoters (5’ ATTGAGATAGTGTGGGGAAGGGG 3’; protospacer adjacent motif in bold) or a gRNA targeting the Adeno-associated virus integration site 1 (AAVS1; 5’ GGGGCCACTAGGGACAGGATTGG 3’; protospacer adjacent motif in bold).12 (link) Cleavage efficiency was evaluated in cells harvested 6 days after electroporation by Sanger sequencing followed by tracking of indels by decomposition (TIDE) analysis.13 (link)
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : Université Paris Cité, Inserm, New York Blood Center, Hôpital Necker-Enfants Malades, Institut des Maladies Génétiques Imagine, Assistance Publique – Hôpitaux de Paris, Université Paris Sciences et Lettres, Institut Curie
Variable analysis
- Pomalidomide (1 mM) treatment
- CRISPR/Cas9 genome editing targeting HBG1 and HBG2 γ-globin promoters or AAVS1 control locus
- γ-globin derepression
- Cleavage efficiency evaluated by Sanger sequencing and TIDE analysis
- Peripheral blood mononuclear cells
- CD34+ cell isolation by magnetic sorting
- Two-phase liquid culture system
- CRISPR/Cas9 targeting AAVS1 control locus
- No treatment control for pomalidomide experiments
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!